Actively Recruiting
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Led by Université de Sherbrooke · Updated on 2026-02-10
36
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
Sponsors
U
Université de Sherbrooke
Lead Sponsor
C
CHU de Quebec-Universite Laval
Collaborating Sponsor
AI-Summary
What this Trial Is About
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 50 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks
CONDITIONS
Official Title
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 50 to 80 years
- Diagnosed with MASLD defined by liver steatosis and abdominal obesity according to International Diabetes Federation criteria
- All women must be post-menopausal
You will not qualify if you...
- Advanced liver fibrosis (stage F3 or higher) or liver stiffness over 10 kPa
- Serum ALT levels greater than three times the normal upper limit
- Signs of portal hypertension
- Other liver diseases besides MASLD
- Previous diagnosis of diabetes
- Overt cardiovascular or kidney disease, cancer (except non-melanoma skin cancer), or other uncontrolled medical conditions
- Any contraindication to MRI
- Previous intolerance or allergy to nicotinic acid
- Participation in a research study involving radiation exposure within the past two years
- Allergy to eggs
- Smoking more than 1 cigarette per day or consuming more than 2 alcoholic beverages daily
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre de recherche du CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
Research Team
F
Frédérique Frisch
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here